Literature DB >> 32557716

Vancomycin population pharmacokinetics and dosing recommendations in haematologic malignancy with augmented renal clearance children.

Chun-Le Lv1, Jie-Jiu Lu1, Ming Chen1, Ren Zhang1, Qiao-Chuan Li2, Yi-Yu Chen1, Tao-Tao Liu1.   

Abstract

WHAT IS KNOWN AND
OBJECTIVES: Augmented renal clearance (ARC) is characterized by enhanced renal clearance, which leads to insufficient vancomycin exposure and treatment failure. In haematologic malignancy patients, determination of optimal vancomycin dosage is essential because of high stake of life-threatening bacterial infection and increased clearance. The aim of this study was to describe vancomycin pharmacokinetic parameters in haematologic malignancy with augmented renal clearance children and define the appropriate dosing regimen to achieve an AUC0-24h /MIC ≥400.
METHODS: Hematologic malignancy with ARC children was enrolled in this retrospective study. The vancomycin PPK model was established by non-linear mixed-effects modelling programme. Goodness-of-fit (GOF) plots, non-parametric bootstrap, normalized prediction distribution error (NPDE) and visual predictive checks (VPCs) were carried out for internal evaluation of the final model. Monte Carlo simulation method was used to stimulate the optimal dosage regimens.
RESULTS: Fifty-three patients with 106 samples were included. A one-compartment model with first-order elimination was developed, and the final model was as follows: CL (L/h) = 6.32×(WT/70)0.75  × e0.0467 ; V(L) = 39.6×(WT/70), where WT denotes weight (kg). The internal validation of the model showed a good prediction performance. Monte Carlo simulation results showed that when MIC was 0.5 mg/L or 1 mg/L, the recommended doses to achieve a target of AUC0-24h /MIC ≥400 were 25 to 40 and 50 to 75 mg/kg/d, respectively. With decreasing weight, the recommended dosage to achieve an AUC0-24h /MIC ≥400 increased. WHAT IS NEW AND
CONCLUSION: A one-compartment vancomycin PPK model was established in haematologic malignancy with augmented renal clearance children with weight with allometric scaling as a significant covariate. When MIC was 1 mg/L, current recommended paediatric dosages were insufficient in haematologic malignancy with augmented renal clearance children and should be increased.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  augmented renal clearance; children; haematologic malignancy; optimal dosage regimens; vancomycin

Mesh:

Substances:

Year:  2020        PMID: 32557716     DOI: 10.1111/jcpt.13206

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  5 in total

1.  Population Pharmacokinetics and Pharmacodynamics of Vancomycin in Pediatric Patients With Various Degrees of Renal Function.

Authors:  Chanika Chuphan; Waroonrat Sukarnjanaset; Thanyawee Puthanakit; Thitima Wattanavijitkul
Journal:  J Pediatr Pharmacol Ther       Date:  2022-07-06

2.  Knowledge, attitudes, and practices related to augmented renal clearance among pediatricians in China: A cross-sectional study.

Authors:  Ran Zhou; Yuting Fang; Chunyan Wang; Shusheng Zhou
Journal:  Medicine (Baltimore)       Date:  2021-08-13       Impact factor: 1.817

3.  Population Pharmacokinetic Study of Cefathiamidine in Infants With Augmented Renal Clearance.

Authors:  Bin Du; Yue Zhou; Bo-Hao Tang; Yue-E Wu; Xin-Mei Yang; Hai-Yan Shi; Bu-Fan Yao; Guo-Xiang Hao; Dian-Ping You; John van den Anker; Yi Zheng; Wei Zhao
Journal:  Front Pharmacol       Date:  2021-03-15       Impact factor: 5.810

4.  The relationship between vancomycin AUC/MIC and trough concentration, age, dose, renal function in Chinese critically ill pediatric patients.

Authors:  Jihui Chen; Xiaohui Huang; Shuhong Bu; Xiaoxiao Chen; Jia Zhou; Xinzhu Liu; Xiaowen Guo; Lixia Li; Jian Zhang
Journal:  Pharmacol Res Perspect       Date:  2021-12

5.  Population Pharmacokinetics and Dosing Optimization of Vancomycin in Infants, Children, and Adolescents with Augmented Renal Clearance.

Authors:  Cui-Yao He; Pan-Pan Ye; Bin Liu; Lin Song; John van den Anker; Wei Zhao
Journal:  Antimicrob Agents Chemother       Date:  2021-08-02       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.